

1 **Full-length article**

2 **Title page**

3

4 **Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome:**
5 **results from a single Italian Centre study on tocilizumab versus standard of**
6 **care.**

7

8 **Authors:** Luca Quartuccio¹, prof, MD, PhD, Arianna Sonaglia¹, MD, Dennis McGonagle², prof,
9 MD, PhD, Martina Fabris³, MD, Maddalena Peghin⁴, MD, Davide Pecori⁴, MD, Amato De
10 Monte⁵, MD, Tiziana Bove^{5,6}, prof, MD, Francesco Curcio², prof, MD, PhD, Flavio Bassi⁵, MD,
11 Salvatore De Vita^{1*}, prof, MD, Carlo Tascini^{4*}, MD

12 *equally collaborated to this work.

13

14 **Affiliations:** 1Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of
15 Udine, Udine, Italy; 2National Institute for Health Research (NIHR) Leeds Biomedical Research
16 Centre (BRC), Leeds Teaching Hospitals, Leeds, UK; 3Institute of Clinical Pathology, ASUFC,
17 Udine, Italy; 4Infectious Diseases Unit, ASUFC, Udine, Italy; 5Department of Anesthesia and
18 Intensive Care, ASUFC, Udine, Italy; 6Department of Medicine, Anesthesia and Intensive Care
19 Clinic, University of Udine, Udine, Italy.

20 **Correspondence to:**

21 Luca Quartuccio, MD, PhD; ORCID iD: 0000-0002-0134-6439.

22 Clinic of Rheumatology, ASUFC

23 Department of Medicine (DAME), University of Udine, Udine, Italy

24 Email to: luca.quartuccio@asufc.sanita.fvg.it

25 Phone: +39 0432559808

26 Fax to: + 39 0432559472

27

28 **Keywords:** coronavirus, COVID-19, tocilizumab, cytokine, intensive care

29 **Manuscript word count:** 2500

30 **Tables:** 4

31 **Figures:** 1

32 **Supplemental file:** 1

33

34 **Highlights**

- 35 • There is an urgent need for markers of prognosis in COVID-19.
- 36 • Higher inflammatory markers best select tocilizumab treatment.
- 37 • The ward based tocilizumab group showed better responses and less infections than ICU
38 tocilizumab group.
- 39 • The former group may be the best for evaluating the impact of anti-cytokine therapy in COVID-
40 19.
- 41 • The known poor risk factors for COVID-19 infection were present in the TOCI treated rather
42 than in the good prognosis standard of care group.

43

44 **Abstract [250 words]**

45 **Objective**

46 Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-
47 threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine
48 storm”. Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear,
49 and the aim of our study is to address this point.

50 **Methods**

51 Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19
52 pneumonia were evaluated in a single centre retrospective study. Patients were divided in two
53 groups: 42 severe cases (TOCI) with adverse prognostic features including raised CRP and IL-6
54 levels, who underwent anti-cytokine treatments, mostly tocilizumab, and 69 standard of care
55 patients (SOC).

56 **Results**

57 In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI,
58 62% of cases were ventilated and there were 3 deaths (17.8 ± 10.6 days, mean follow up) with 7/26
59 cases remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection.
60 One fatality occurred in the 15 TOCI cases treated on noninvasive ventilation and 1 serious
61 bacterial superinfection. Of the 69 cases in SOC, there was no fatalities and no bacterial
62 complications. The TOCI group had higher baseline CRP and IL-6 elevations ($p < 0.0001$ for both)
63 and higher neutrophils and lower lymphocyte levels ($p = 0.04$ and $p = 0.001$, respectively) with the
64 TOCI ventilated patients having higher markers than non-ventilated TOCI patients.

65 **Conclusion**

66 Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI
67 cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy
68 time in anti-cytokine randomized trials will be key.

69

70 **Funding**

71 This research received no external funding.

72 **Conflicts of Interest:** “The authors declare no conflict of interest.”

73

74 **Introduction**

75 The outbreak of novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome
76 coronavirus 2 (SARS-CoV-2) is a global pandemic [1]. About twenty-five percent of patients have
77 a seriously ill disease. A fraction of them may develop a very severe pneumonia which may
78 progress to acute respiratory distress syndrome (ARDS) or end-organ failure that may be associated
79 with a cytokine storm syndrome [2]. Laboratory features associated with ARDS or death included
80 neutrophilia, coagulation dysfunction [e.g., higher lactate dehydrogenase (LDH) and D-dimer] [3].
81 Markedly high levels of interleukin (IL)-2R, IL-6, IL-10, and TNF- α and the absolute numbers of
82 CD4+ and CD8+ T lymphocytes being markedly low seem to characterize the most severe cases
83 [4]. Starting from the first preliminary experience on the apparent efficacy of tocilizumab in
84 COVID-19 pneumonia [5], many multicenter trials are ongoing to test anti-cytokine treatments in
85 critically ill patients.

86

87 Nevertheless, robust data to predict the outcome of COVID-19 pneumonia after the hospital
88 admission are still lacking [6], though they are urgently needed in order to facilitate the assessment
89 of anti-cytokine treatment efficacy in worse prognosis patient groups and not milder disease. The
90 aim of this retrospective study was to evaluate baseline laboratory and immunological features in
91 patients hospitalized for COVID-19 pneumonia and to explore such parameters in relationship to
92 standard of care (SOC group) therapy versus anti-cytokine therapy, mainly tocilizumab, (TOCI
93 group) that was mostly used either in ventilated patients in the ICU or non-invasively ventilated
94 patients, mostly in the ward setting. Our single centre experience and approach showed that the
95 milder hospitalized SOC group fared well as did cases with cytokine storm treated with
96 tocilizumab outside of the ICU setting without ventilator support. Severe complications including
97 bacterial infections complicated tocilizumab in the ICU setting but not ward-based tocilizumab
98 therapy. Therefore, randomized trials should target non-ICU patients to prevent cytokine storm
99 evolution.

100

101 **Methods**

102 This study was undertaken to identify laboratory features for more serious COVID-19 disease (i.e.,
103 to determine which cases that might theoretically benefit from anti-cytokine drugs). In this
104 monocentric retrospective case-control study, the clinical and immunological characteristics of 111
105 consecutive patients with COVID-19 were analyzed. Patients were admitted to our hospital from
106 February 29 to April 6, 2020. All but 6 patients presented to our hospital with 6 cases transferred
107 from three other hospitals (all of whom eventually received tocilizumab).

108

109 Oral or written consent was obtained from patients. The study was conducted in accordance with
110 the ethical principles of the Helsinki Declaration and ethical approval was given by local Ethics
111 Committee (CEUR-2020-Os-102).

112

113 Besides clinical evaluation, the level of CRP and IL-6, when available, guided the decision towards
114 anti-cytokine treatments. Clinical decisions for the treatment of all these patients were taken usually
115 within the first week after the admission, and during this time, the laboratory tests were repeated.
116 Demographic, clinical and laboratory characteristics, treatments and outcome data were collected.
117 Identification of cases of COVID-19 virus was based on the detection of unique sequences of virus
118 RNA by nucleic acid amplification tests (NAAT) such as RT-PCR with confirmation by nucleic
119 acid sequencing. The following genes were investigated: E gene for screening and then RdRp and N
120 genes of SARS-CoV-2 for confirmation [7].

121

122 Some laboratory data analysed at the admission are reported in table 1, including flow cytometry
123 analysis with antibodies for the following subpopulations: CD19+ B cells, CD3+CD4+ T cells,
124 CD3+CD8+ T cells, CD56+ NK cells, platelet count (cell/microL) and serum IL-6 (pg/ml),

125 measured by CE_IVD electrochemiluminescence immunoassay (Elecsys IL6, Cobas, physiological
126 range < 7pg/ml) with results being available within 48 hours.

127

128 Variables were reported as mean and standard deviation or median and interquartile range (IQR), as
129 appropriate, or frequency rates and percentages if categorical; consequently, comparisons between
130 TOCI and SOC groups were made by parametric tests (t-test for two independent samples) or non
131 parametric tests (Mann-Whitney test) for continuous variables. Proportions were compared by χ^2
132 test, or Fisher exact test. Bivariate correlation was made by two tailed Pearson or Spearman tests.
133 All statistical analyses were performed using SPSS version 15.0 software (SPSS Inc). For
134 unadjusted comparisons, a 2-sided α of less than .05 was considered statistically significant. No
135 corrections were made for multiple comparisons due to the explorative nature of the study.

136

137 When the laboratory parameters were available, the patients were classified into two groups: the
138 first group comprised 42 cases who developed a serious COVID-19 disease that were deemed
139 suitable for tocilizumab 8 mg/kg intravenously as a single infusion. In TOCI failures, two patients
140 were then treated with anakinra 200 mg/day subcutaneously for three consecutive days. A second
141 group of 69 cases who received supportive therapy [standard of care group (SOC)] comprised those
142 initially admitted to the hospital for COVID-19, and who were treated with SOC based on clinical
143 and laboratory features (Table 1).

144

145 **Results**

146 **Patients' characteristics and outcome**

147 Table 1 reports the main demographic and clinical features of the two groups. Patients were
148 predominantly male (77/111, 69.4%) with a mean age of 58.5±13.6 years. Patients in TOCI were
149 slightly older than SOC (p=0.02) (table 1). Globally, at the hospital admission, resting oxygen
150 saturation equal or below 93% was available for 45 patients (40.5%).

151

152 Antiviral treatments were employed in 100% of TOCI group and 80% of SOC group (Table 1).
153 Notably, nearly 40% of TOCI group received glucocorticoids but none of the SOC group did (Table
154 1). There was no difference between groups regarding the time of reaching a negative swab test
155 (supplemental file).

156

157 Among TOCI group, 18 (43%) patients were originally referred to the Infectious Disease Unit with
158 3 being subsequently transferred to ICU before tocilizumab administration (Figure 1) with 24/42
159 patients (57%) ICU transfers within 24 hours of hospital admission. The majority of patients
160 received tocilizumab in the ICU (27/42, 64.3%) with the remaining 15 cases receiving TOCI on the
161 ward. Tocilizumab was administered after a mean time of 8.4 ± 3.7 days from disease onset as add-
162 on treatment. Of the 27 patients that were transferred to ICU, 26 (96.3%) were intubated with
163 subsequent tracheostomies in 8 (7.2%), while only one was on noninvasive ventilation.

164

165 There were no fatalities in the SOC group (Figure 1). Overall, at April 18, 2020, 4/42 TOCI patients
166 had died (9.5%). Of the TOCI ventilated patients 15/26 (57.7%) had a good outcome. When
167 combined with fatality rate, 11/26 (42.3%) patients in the TOCI ventilated group can be deemed as
168 non-responders. By contrast, 15/16 (93.7%) TOCI non-ventilated patients can be deemed as
169 responders with a single fatality (Figure 1). Importantly, at the hospital admission, TOCI patients
170 who required invasive ventilation showed higher levels of inflammation markers, higher LDH and
171 lower lymphocyte count than non-ventilated TOCI patients (Table 2).

172 Eighteen out 111 patients (16.2%) experienced bacterial superinfection that were almost exclusively
173 in the TOCI group (Figure 1). Three out of four deaths and 17/18 bacterial complications occurred
174 in ICU (all 3 deaths as well as all the bacterial complications occurred in patients on ventilators or
175 in the non-ventilated TOCI group (Figure 1).

176

177 While all the patients in the SOC group recovered, in the TOCI group, 9/42 (21.4%) patients
178 completely recovered, and 21/42 (50%) patients showed a clear and rapid improvement after
179 tocilizumab. A rapid improvement on anakinra after tocilizumab occurred in one case. In the 21
180 recovered TOCI treated group complicating infections arose in 11 (52.4%). In the remaining 12
181 non-responder patients, four of them died, including one treated with anakinra after tocilizumab
182 failure, and almost all showed co-morbidities including hypertension, obesity, ischemic heart
183 disease or diabetes, or experienced superinfections, which substantially complicated the course.

184

185 **Retrospective laboratory marker comparison between treatment groups**

186 At hospital admission, TOCI group showed a significantly higher level of systemic inflammation as
187 resulted by the significant difference of CRP levels [mg/L, median (IQR)] [79.05 (47.8-186.22) vs
188 24.1 (7.3-72.6) $p < 0.0001$], and IL-6 levels [pg/mL, median (IQR)] [63.5 (37.25-135.5) vs 18.5
189 (10.25-33), $p < 0.0001$]. Also, some other laboratory features mirrored a higher level of systemic
190 disease and organ damage in TOCI group, such as LDH [IU/L, median (IQR)] [625 (482-829) vs
191 442 (375-577), $p = 0.001$] and CK [IU/L, median (IQR)] [134 (84.5-365.5) vs 93 (57-146), $p = 0.007$].

192

193 The TOCI group showed a significantly higher neutrophil count (cells/microL) [4565 (3062.5-6190)
194 vs 3670 (2285-4905), $p = 0.04$], lower lymphocyte count [cell/microL, median (IQR)] [685 (545-
195 1022.5) vs 940 (760-1195), $p = 0.001$], CD4+ T cell [244.5 (158.75-406.25) vs 370 (269.5-497),
196 $p = 0.02$], CD8+ T cell subpopulation [77 (48-195.75) vs 180 (111-366), $p = 0.004$]. Also, neutrophil
197 to lymphocyte ratio (NLR) was significantly higher in TOCI group than in SOC group [5.6 (3.5-
198 11.8) vs 3.6 (2.2-5.4), $p = 0.001$]. The TOCI group also showed basal higher levels of LDH
199 ($p = 0.001$) and CK ($p = 0.007$), possibly indicating cardiac injury that is a known bad prognostic sign.

200

201 Table 3A reports the correlations between CRP levels and the levels of the other biomarkers in the
202 whole population (TOCI+SOC) and in the whole population after excluding those patients with the

203 worst clinical presentation at the admission (N=24). A moderate to high correlation (>0.5) was
204 found between CRP and the following variables: D-dimer, LDH, neutrophil count and NLR (table
205 2).

206 By excluding those patients admitted to the ICU within 24 hours (i.e., the most serious) (table 3B),
207 CRP and IL-6 remained statistically significant as discriminant variables between the two groups
208 (Table 3). Yet, correlations between CRP and IL-6, total white blood cell count, neutrophil count,
209 NLR, LDH were still significant (table 3B).

210 Furthermore, the same analysis in the whole cohort by splitting the two group (N=42 for TOCI and
211 N=69 for SOC), showed that baseline CRP value correlated with IL-6, D-dimer, LDH, WBC,
212 neutrophil count and NLR only in the SOC group, while in the TOCI group, baseline CRP
213 correlated only with LDH, WBC, neutrophil and NLR (data not shown).

214

215 **Discussion**

216

217 Our retrospective study was designed to evaluate which baseline standardized laboratory features in
218 hospitalized COVID-19 pneumonia may facilitate optimal employment of experimental anti-
219 cytokine therapy [8, 9]. Some case reports and one case series on the treatment with tocilizumab
220 have been reported in the literature, suggesting some benefits in seriously ill patients [10-16]. More
221 clearly, our data suggested that tocilizumab treatment in patients with cytokine storm features may
222 be more effective outside of the ICU setting in non-ventilated patients. However, there were
223 differences in the degree of inflammation between non-ventilated and ventilated patients treated
224 with tocilizumab, so it cannot be inferred that use of tocilizumab prior to ICU admission is superior,
225 given the generally milder inflammation in the former group. Also, serious superimposed bacterial
226 infections were largely confined to the ICU. More worryingly, half the ICU ventilated patients
227 treated with TOCI remain ventilated or have died with only half of this group showing meaningful
228 clinical improvement so far.

229

230 Our findings confirmed that the milder patient group receiving standard of care therapy without the
231 utilization of tocilizumab all made full recoveries. Our findings do point towards trials focused on
232 the earlier use of such therapeutic strategies. Notably, our SOC and TOCI groups were different in
233 terms of co-treatments, which could have affected the overall outcome, and all of the TOCI cases
234 also received antiviral therapy. These findings are preliminary and the results of ongoing
235 randomized controlled trials will definitely clarify anti-cytokine use.

236

237 In our study, neutrophilia, lymphopenia, in particular low CD8+ T cell count rather than CD4+ T
238 cell, higher CRP, higher LDH and higher CK showed the highest significance to distinguish the two
239 patient groups at initial hospital admission. Also, serum IL-6 was significantly higher in the TOCI
240 group, thus reflecting the very high inflammatory state of those patients at baseline. Very recently,
241 IL-6 serum levels were also closely correlated with viral load in critically ill patients and it is
242 important to point out that all our patients belonging to TOCI group received anti-viral agents [17].
243 Notably, baseline CRP and IL-6 continued to distinguish the two groups (TOCI versus SOC) even
244 after excluding the most seriously ill patients from analyses. Thus, these biomarkers could be useful
245 for decision making. Notably, a higher NLR, as well as a higher monocyte to lymphocyte ratio,
246 have been associated with mortality and imaging progression in hospitalized patients for COVID-19
247 [18-20]. It is well known that NLR is a biomarker for poor outcome even in various cancers [21].

248

249 Lymphocyte biology probably plays a great role in the pathogenesis of COVID-19 disease [4, 22-
250 25].

251 Since CD4+ T cells and CD8+ T cells are a crucial arm against infections [26], our findings also
252 indicated that the lymphopenia in the TOCI group may be relevant for secondary infections. Given
253 that, treatment with tocilizumab might favor the persistence of the virus and iatrogenic infections.

254 Anakinra might be safer and more flexible than repeating tocilizumab infusion in seriously ill
255 patients.

256

257 A role for anticoagulation is increasingly recognized in severe COVID-19 [27, 28]. In our study, a
258 significant correlation between CRP and D-dimer, as well as with LDH and neutrophil count (and
259 NLR) was shown. Very recent data showed that low molecular weight heparin or unfractionated
260 heparin at prophylactic doses are associated with a reduced short-term mortality in more severe
261 COVID-19 patients [28], and most of our patients, particularly, in ICU, were administered heparin
262 which may have impacted on the overall outcome. Moreover, inflammatory diseases carry a higher
263 risk of thrombosis, as seen in chronic autoimmune diseases [29]. It remains to be seen whether the
264 possible efficacy of anti-cytokine therapy may be even to mitigate against immunothrombosis.
265 Increased levels of LDH and CK may also reflect the level of the organ damage in a systemic
266 disease, as occurs in the macrophage activation syndrome [30], where a hypercoagulable state often
267 complicates the course, and it may be the case for COVID-19. Thus, it is not surprisingly that LDH
268 has been already noticed as biomarker of severity as long as neutrophils, in COVID-19 [3, 31].

269

270 This study has several limitations. It is a retrospective study, with some missing data due to the
271 emergency context in which it has been realized. No conclusions on the efficacy and safety of
272 treatment approach employed can be provided. Six patients were transferred from other hospitals so
273 original baseline values from the first admission were unavailable. About 50% of the TOCI group
274 were admitted to the ICU within 24 hours from admission, thus they already presented a more
275 serious disease at the time of admission. The follow-up was limited from our hospital admission to
276 discharge. Finally, measurement of viral load was not available. Nevertheless, the cohort is
277 monocentric and it showed similar characteristics to those reported by Wang et al. [2], thus
278 supporting the results, though preliminary.

279

280 To conclude, our study showed that TOCI treated patients COVID-19 pneumonia were at the
281 highest risk of cytokine storm [32]. Tocilizumab use prior to ventilation in ICU may be optimal
282 since 50% of such cases died, remain ventilated and show serious superinfection. Whether the use
283 of tocilizumab prior to ventilation will be vindicated in randomized trials is of major interest. Our
284 findings also showed that cases receiving tocilizumab on ventilation generally had higher levels of
285 inflammation than non-ventilated TOCI treated subjects, possibly suggesting that the latter group
286 has an intrinsically milder disease with a better prognosis. Timing of anti-cytokine therapy is a key
287 issue.

288

289 **Contributions**

290 LQ designed data collection tools, monitored data collection for the whole study, wrote the
291 statistical analysis plan, cleaned and analysed the data, drafted and revised the paper. He is
292 guarantor. AS collected the data, analysed the data, and revised the paper. FC, MF, TB, ADM, FB,
293 MP, DP collected the data, analysed the data, and revised the paper. SDV, DM analysed the data,
294 drafted and revised the paper. CT designed data collection tools, analysed the data, revised the
295 paper.

296

297 **Acknowledgements**

298 We thank the following colleagues for their valued contribution to this work: Ginevra De Marchi,
299 MD, Miriam Isola, prof, BS, Sara Zandonella, MD, Ivan Giovannini, MD, Elena Treppo, MD,
300 Donatella Colatutto, MD, Marco Binutti, MD, Giulia Del Frate, MD, Roberto Agarinis, MD,
301 Valeria Manfrè, MD, Daniela Cesselli, prof, MD, Roberta Giacomello, BS, Federica D'Aurizio,
302 MD, Michele Zuliani, MD, Corrado Marescalco, MD.

303

304 **Funding info**

305 This research received no external funding.

306

307 **Ethical approval information**

308 The study was conducted in accordance with the ethical principles of the Helsinki Declaration.

309 Patients' consents for using data for research purpose were obtained at the time of hospital
310 admission.

311 Ethical approval for the present retrospective observational study was given by “Comitato Etico

312 Unico Regionale (CEUR)”, with the following registration number: CEUR-2020-Os-102.

313 Patients treated with tocilizumab were then enrolled into the observational part of the TOCIVID-19

314 Italian study (EudraCT: 2020-001110-38), a single arm, open-label trial on the efficacy and safety

315 of tocilizumab in COVID-19 pneumonia.

316

317 **Data sharing statement**

318 The data that support the findings of this study are available on request from the corresponding

319 author, [LQ].

320

321 **References**

322 1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel

323 coronavirus in Wuhan, China. *Lancet* **2020**; 395: 497-506.

324 2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019

325 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. **2020** Feb 7. doi:

326 10.1001/jama.2020.1585.

327 3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress

328 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,

329 China. *JAMA Intern Med*. **2020** Mar 13. doi: 10.1001/jamainternmed.2020.0994.

330 4. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate

331 coronavirus disease 2019. *J Clin Invest*. **2020** Apr 13. pii: 137244. doi: 10.1172/JCI137244.

- 332 5. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
333 center experience. *J Med Virol.* **2020** Apr 6. doi: 10.1002/jmv.25801.
- 334 6. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and
335 prognosis of covid-19 infection: systematic review and critical appraisal. *BMJ.* **2020** Apr
336 7;369:m1328. doi: 10.1136/bmj.m1328.
- 337 7. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease and
338 Tools for Detection *ACS Nano.* 2020 Mar 30: acsnano.0c02624. Published online 2020 Mar
339 30. doi: 10.1021/acsnano.0c02624.
- 340 8. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of
341 people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical
342 immunologists from China. *Clin Immunol.* **2020** Mar 25;214:108393. doi:
343 10.1016/j.clim.2020.108393
- 344 9. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
345 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like
346 Disease. *Autoimmun Rev.* **2020** Apr 3:102537. doi: 10.1016/j.autrev.2020.102537
- 347 10. Xu XL, Han MF, Li TT, et al. Effective treatment of severe COVID-19 patients with
348 tocilizumab. *ChinaXiv.* **2020**;202003(00026):V1.
- 349 11. Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to
350 treat Covid-19-related respiratory failure: a case report. *Ann Oncol.* **2020** Apr 2. pii: S0923-
351 7534(20)36387-0. doi: 10.1016/j.annonc.2020.03.300.
- 352 12. De Luna G, Habibi A, Deux JF, et al. Rapid and Severe Covid-19 Pneumonia with Severe
353 Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab. *Am J*
354 *Hematol.* **2020** Apr 13. doi: 10.1002/ajh.25833.
- 355 13. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT
356 findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. *Diagn*
357 *Interv Imaging.* **2020** Mar 31. pii: S2211-5684(20)30087-5. doi: 10.1016/j.diii.2020.03.010.

- 358 14. Di Giambenedetto S, Ciccullo A, Borghetti A, et al.; GEMELLI AGAINST COVID-19
359 group (Members are listed in the Acknowledgments section). Off-label Use of Tocilizumab
360 in Patients with SARS-CoV-2 Infection. *J Med Virol.* **2020** Apr 16. doi: 10.1002/jmv.25897.
- 361 15. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-
362 19? *J Transl Med.* **2020** ;18(1):164. doi: 10.1186/s12967-020-02339-3. 1
- 363 16. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
364 center experience. *J Med Virol.* **2020** Apr 6. doi: 10.1002/jmv.25801.
- 365 17. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2viral load (RNAemia) is
366 closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-
367 19 patients. *Clin Infect Dis.* 2020 Apr 17;ciaa449. doi: 10.1093/cid/ciaa449.
- 368 18. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for
369 mortality in hospitalized patients with COVID-19. *Clin Infect Dis.* **2020** Mar 12. pii:
370 ciaa248. doi: 10.1093/cid/ciaa248.
- 371 19. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19
372 in Wuhan, China. *J Infect.* **2020** Apr 10. pii: S0163-4453(20)30208-5. doi:
373 10.1016/j.jinf.2020.04.002.
- 374 20. Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus
375 disease 2019 (COVID-19) patients. *Aging (Albany NY).* **2020** Apr 10; 12. doi:
376 10.18632/aging.102999.
- 377 21. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte
378 ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* **2014**;106
379 (6):dju124. doi: 10.1093/jnci/dju124.
- 380 22. Ji D, Zhang D , Xu J, et al. Prediction for Progression Risk in Patients with COVID-19
381 Pneumonia: the CALL Score. *Clin Infect Dis.* **2020** Apr 9. pii: ciaa414. doi:
382 10.1093/cid/ciaa414.

- 383 23. Yang X, Yu Y, Xu J, et al. Clinical Course and Outcomes of Critically Ill Patients With
384 SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective,
385 Observational Study. *Lancet Respir Med.* **2020** Feb 24. pii: S2213-2600(20)30079-5. doi:
386 10.1016/S2213-2600(20)30079-5.
- 387 24. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
388 China. *N Engl J Med.* **2020** Feb 28. doi: 10.1056/NEJMoa2002032.
- 389 25. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid
390 and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect.*
391 **2020**; 9: 761-770. doi: 10.1080/22221751.2020.1747363.
- 392 26. Zhao J, Zhao J, Mangalam AK, et al. Airway Memory CD4(+) T Cells Mediate Protective
393 Immunity against Emerging Respiratory Coronaviruses. *Immunity.* **2016**; 44: 1379-91. doi:
394 10.1016/j.immuni.2016.05.006.
- 395 27. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels
396 obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory
397 distress syndrome working hypothesis. *Crit Care Resusc.* **2020** Apr 15.
- 398 28. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased
399 mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*
400 **2020**; doi: 10.1111/jth.14817.
- 401 29. Quartuccio L. Risk of thrombosis in Sjögren syndrome: the open question of endothelial
402 function immune-mediated dysregulation. *J Rheumatol.* **2017**; 44: 1106-8. doi:
403 10.3899/jrheum.170462.
- 404 30. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19
405 inpatients in Wuhan. *J Allergy Clin Immunol.* **2020** Apr 12. pii: S0091-6749(20)30495-4.
406 doi: 10.1016/j.jaci.2020.04.006.
- 407 31. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm:
408 Immunopathology in COVID-19. *Arthritis Rheumatol.* **2020** Apr 15. doi: 10.1002/art.41285.

409 32. Quartuccio L, Semerano L, Benucci M, Boissier MC, De Vita S. Urgent avenues in the
410 treatment of COVID-19: targeting downstream inflammation to prevent catastrophic
411 syndrome. *Joint Bone Spine* **2020**; 87: 191-3.

412

413 **Table 1.** Main comparisons between treatment groups at day 0 (hospital admission).

414 **Legend:** SD, standard deviation; WBC, white blood cells; CRP, C-reactive protein; LDH, lactate

	TOCI (N=42)	Number available observations, N (%)	of SOC (N=69)	Number available observations, N (%)	of P value
Age, mean±SD	62.4±11.8	42 (100)	56.2±14.2	69 (100)	0.02
Gender, male (%)	33 (78.6)	42 (100)	44 (63.8)	69 (100)	0.1
Days from onset to admission, median (IQR)	6 (3.25-7)	42 (100)	7 (3.9-5)	69 (100)	0.18
Hypertension (%)	20 (47.6)	42 (100)	21 (30.4)	69 (100)	0.11
Charlson's index ≥ 2 (%)	5 (11.9)	42 (100)	12 (17.4)	69 (100)	0.44
Antivirals* (%)	42 (100)	42 (100)	54 (78.3)	69 (100)	0.003
Antimalarials** (%)	39 (92.9)	42 (100)	53 (76.8)	69 (100)	0.05
Glucocorticoids*** (%)	16 (38.1)	42 (100)	0	69 (100)	<0.0001
Antibiotics# (%)	12 (28.6)	42 (100)	9 (23.1)	69 (100)	0.07
LMWH (%)	31 (73.8)	42 (100)	15 (21.7)	69 (100)	<0.0001
WBC count (cells/microL), median (IQR)	5540 (4270-7140)	39 (92.9)	5230 (3705-6305)	69 (100)	0.14
Neutrophil count (cells/microL), median (IQR)	4565 (3062.5-6190)	34 (80.2)	3670 (2285-4905)	69 (100)	0.04
Lymphocytes (cells/microL), median (IQR)	685 (545-1022.5)	34 (80.2)	940 (760-1195)	69 (100)	0.001
Neutrophil/lymphocyte ratio, median (IQR)	5.6 (3.5-11.8)	34 (80.2)	3.7 (2.2-5.4)	69 (100)	0.001
CD4+ T cells (cells/microL), median (IQR)	244.5 (158.75-406.25)	24 (57.1)	370 (269.5-497)	25 (36.2)	0.02
CD8+ T cells (cells/microL), median (IQR)	77 (48-195.75)	24 (57.1)	180 (111-366)	25 (36.2)	0.004
CD19+ B cells (cells/microL), median (IQR)	97 (67.5-110.5)	17 (40.5)	112.5 (83-174.5)	24 (34.8)	0.12
CD56+ NK cells (cells/microL), median (IQR)	128 (56-208.5)	17 (40.5)	150 (131-237)	23 (33.3)	0.16
Platelet count (cells/microL), median (IQR)	157000 (125500-195500)	39 (92.8)	166000 (136000-216500)	69 (100)	0.24
CRP (mg/L), median (IQR)	79.05 (47.77-186.22)	40 (95.2)	24.1 (7.35-72.6)	69 (100)	<0.0001
D-dimer (ng/ml), median (IQR)	835 (602-1163)	14 (33.3)	660 (270.5-846.5)	25 (36.2)	0.1
LDH (IU/L), median (IQR)	625 (482-829)	35 (83.3)	442 (375-577)	67 (97.1)	0.001
CK (IU/L), median (IQR)	134 (84.5-365.5)	29 (69.0)	93 (57-146)	65 (94.2)	0.007
IL-6 (pg/ml), median (IQR)	63.5 (37.2-135.5)	34 (80.9)	18.5 (10.25-33)	56 (81.1)	<0.0001

415 dehydrogenase; CK, creatine kinase; LMWH, low molecular weight heparin; BIOLOGIC, anti-
416 cytokine treatment group; SOC standard of care group.

417 *Lopinavir/Ritonavir (L/R) in 56 patients (all as first-line antiviral treatment); Darunavir/Cobicistat
418 (D/C) in 57 patients (as first-line antiviral treatment in 40, as second-line in 17); Remdesivir in 3
419 patients, all as second- or third-line treatment. Seventeen patients switched from L/R to D/C due to
420 side effects.

421 **Hydroxychloroquine in 87 patients; chloroquine in 5 patients.

422 ***Glucocorticoids were always administered intravenously at the dose of 1 mg/kg of
423 methylprednisolone in the first two days, then steroids were tapered and finally suspended in 7
424 days.

425 #as prophylactic treatment, before tocilizumab therapy.

426

427

428 **Table 2.** Laboratory marker comparison between the two Tocilizumab treated subgroups.

	TOCI on NIV/O2 (N=16)	TOCI on ventilators (N=26)	P value
CRP, mg/L	59.3 (21.6-112.7)	114.6 (5.25-210)	0.04
IL-6, pg/ml	58 (28.45-78.5)	78.8 (46-161)	0.06
WBC, cell/microL	4425 (3210-6115)	6180 (5230-8130)	0.009
Neutrophil, cell/microL	3130 (2310-4885)	7235 (5430-9072)	0.01
Lymphocyte, cell/microL	1020 (635-1165)	650 (445-775)	0.01
NLR	3.5 (2.5-5.1)	8.2 (4.7-15.7)	0.001
LDH, IU/L	494 (246.5-599)	744 (580.75-1057)	0.001
CK, IU/L	101 (78-179)	197 (104.5-382.75)	0.13

429 Legend: CRP, C-reactive protein; IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase;
430 WBC, white, blood cell count; NLR, neutrophil to lymphocyte ratio. Data are presented as median
431 (IQR).
432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453 **Table 3A.** Bivariate correlations between CRP levels and other biomarkers.

Variable	Spearman's rho correlation coefficient	P value	Number of observations, N (%)
IL-6	0.46	<0.0001	90 (81.1)
D-dimer	0.63	<0.0001	39 (35.1)
LDH	0.62	<0.0001	102 (91.9)
CK	0.23	0.03	94 (84.7)
Total WBC count	0.49	<0.0001	108 (97.3)
Neutrophil count	0.60	<0.0001	103 (92.8)
Lymphocyte count	-0.26	0.002	103 (92.8)
NLR	0.57	<0.0001	103 (92.8)

454 Legend: IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC, white blood cell
455 count; NLR, neutrophil to lymphocyte ratio.

456

457

458 **Table 3B.** Bivariate correlations between CRP levels and other biomarkers by excluding those
459 patients transferred to ICU within 24 hours from the admission (N=24).

460

Variable	Spearman's rho correlation coefficient	P value	Number of observations, N (%)
IL-6	0.42	0.0002	71 (63.4)
D-dimer	0.62	0.0002	31 (27.9)
LDH	0.48	<0.0001	82 (73.9)
CK	0.12	0.29	78 (70.3)
Total WBC count	0.43	<0.0001	87 (78.4)
Neutrophil count	0.50	<0.0001	83 (74.8)
Lymphocyte count	-0.1	0.38	83 (74.8)
NLR	0.44	<0.0001	83 (74.8)

461 Legend: IL, interleukin; LDH, lactate dehydrogenase; CK, creatine kinase; WBC, white, blood cell
462 count; NLR, neutrophil to lymphocyte ratio.


463

464


465

466 **Legend to the figure**

467 **Figure 1.** The chart illustrates the outcomes of the two treatment groups.



469 **Legend:** TOCI, anti-cytokine group; SOF, standard of care group; MOF, multi-organ failure; ICU,
470 intensive care unit; NIV, noninvasive ventilation; PE, pulmonary embolism.



Group	Total N. pts	N. Events	Time, days [median, IQR]
SOC	61	59	19 [15-26]
TOCI	40	34	22 [11-33]
Overall	101	93	21 [14-27]